Globus Medical Inc (GMED) FinancialsGMEDFinancialGlobus Medical Inc

Globus Medical, Inc. (GMED) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Musculoskeletal Solutions, accounting for 96.7% of total sales, equivalent to $763.54M. Another important revenue stream is Enabling Technologies. Understanding this composition is critical for investors evaluating how GMED navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Globus Medical, Inc. maintains a gross margin of 65.68%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 24.76%, while the net margin is 19.20%. These profitability ratios, combined with a Return on Equity (ROE) of 11.81%, provide a clear picture of how effectively GMED converts its operational activities into shareholder value.

In the context of the broader market, GMED competes directly with industry leaders such as ALGN and GKOS. With a market capitalization of $11.08B, it holds a significant position in the sector. When comparing efficiency, GMED's gross margin of 65.68% stands against ALGN's 72.82% and GKOS's 81.67%. Such benchmarking helps identify whether Globus Medical, Inc. is trading at a premium or discount relative to its financial performance.

In Q2 2026, Globus Medical reported revenue of $789.6 million, a 6% year-over-year increase, and a non-GAAP EPS of $1.34, up 56% year-over-year, indicating strong operational performance. The gross margin has also improved to 65.68%, showcasing effective cost management.